Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OVCAR3 RNAseq]
We performed RNA sequencing on OVCAR3 parental cells treated with either control vehicle for 4 days or 300 nM INX-315 for 7 days. Overall design: OVCAR3 parental cells were treated with either control DMSO for 4 days or 300 nM INX-315 for 7 days. 3 replicates per group were collected.